Maxim Group Maintains Capricor Therapeutics(CAPR.US) With Buy Rating, Maintains Target Price $25
Capricor Therapeutics: Promising Advances in Duchenne Cardiomyopathy Treatment Drive Buy Rating
Beyond The Numbers: 7 Analysts Discuss Capricor Therapeutics Stock
H.C. Wainwright Maintains Capricor Therapeutics(CAPR.US) With Buy Rating, Maintains Target Price $77
Express News | HC Wainwright & Co. Reiterates Buy on Capricor Therapeutics, Maintains $77 Price Target
Capricor Therapeutics Completes Submission Of Biologics License Application To FDA for Deramiocel
Green7plus : Please advise when it expects to FDA decision?
Trytosaveabit OP Green7plus : Haven’t seen a PDUFA date yet?